Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 1
2002 1
2004 1
2005 2
2006 2
2007 1
2008 1
2010 2
2013 2
2014 3
2015 1
2016 1
2017 1
2018 2
2019 2
2020 1
2021 1
2022 7
2023 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F, Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A, Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R. Hashimoto N, et al. Among authors: atake k. BMC Psychiatry. 2023 Jun 28;23(1):473. doi: 10.1186/s12888-023-04908-4. BMC Psychiatry. 2023. PMID: 37380997 Free PMC article.
Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
Okada T, Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, Iida H, Ochi S, Takaesu Y, Tsuboi T, Iga JI, Ichihashi K, Muraoka H, Furihata R, Yasui-Furukori N, Usami M, Onitsuka T, Ogasawara K, Tagata H, Takeshima M, Ohi K, Numata S, Hashimoto N, Yamada H, Makinodan M, Komatsu H, Hishimoto A, Yamagata H, Kido M, Kubota C, Atake K, Yamada H, Nagasawa T, Matsumoto J, Miura K, Inada K, Watanabe K, Suda S, Hashimoto R. Okada T, et al. Among authors: atake k. J Clin Psychopharmacol. 2022 Nov-Dec 01;42(6):591-593. doi: 10.1097/JCP.0000000000001604. Epub 2022 Oct 3. J Clin Psychopharmacol. 2022. PMID: 36193896 No abstract available.
Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.
Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J, Takaesu Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M, Tagata H, Yamada H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, Hashimoto R. Ogasawara K, et al. Among authors: atake k. Neuropsychopharmacol Rep. 2022 Jun;42(2):221-225. doi: 10.1002/npr2.12245. Epub 2022 Mar 10. Neuropsychopharmacol Rep. 2022. PMID: 35272393 Free PMC article.
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".
Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, Ichihashi K, Iida H, Ohi K, Muraoka H, Kodaka F, Ide K, Hashimoto N, Iga JI, Ogasawara K, Atake K, Takaesu Y, Nagasawa T, Komatsu H, Okada T, Furihata R, Kido M, Kikuchi S, Kubota C, Makinodan M, Ochi S, Takeshima M, Yamagata H, Matsumoto J, Miura K, Usami M, Kishimoto T, Onitsuka T, Katsumoto E, Hishimoto A, Numata S, Yasui-Furukori N, Watanabe K, Hashimoto R. Inada K, et al. Among authors: atake k. Neuropsychopharmacol Rep. 2022 Dec;42(4):502-509. doi: 10.1002/npr2.12293. Epub 2022 Oct 18. Neuropsychopharmacol Rep. 2022. PMID: 36254805 Free PMC article.
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders.
Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H, Ohi K, Ochi S, Ide K, Hashimoto N, Usami M, Nakamura T, Komatsu H, Okada T, Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T, Makinodan M, Horai T, Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A, Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K, Inada K, Otsuka K, Hashimoto R. Fukumoto K, et al. Among authors: atake k. Neuropsychopharmacol Rep. 2023 Mar;43(1):33-39. doi: 10.1002/npr2.12301. Epub 2022 Nov 16. Neuropsychopharmacol Rep. 2023. PMID: 36394160 Free PMC article.
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu H, Tsuboi T, Tokutani A, Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K, Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M, Usami M, Makinodan M, Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K, Kido M, Hishimoto A, Ueno SI, Watanabe K, Inada K, Hashimoto R. Ochi S, et al. Among authors: atake k. Int J Neuropsychopharmacol. 2022 Oct 25;25(10):818-826. doi: 10.1093/ijnp/pyac036. Int J Neuropsychopharmacol. 2022. PMID: 35723038 Free PMC article.
32 results